Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Solon Eiendom ASA : Approval and publication of prospectus

Solon Eiendom ASA
Posted on: 16 May 18

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Reference is made to the private placement in Solon Eiendom ASA (the " Company ") of 2,672,721 new shares (the " New Shares ") for gross proceeds of NOK 67,486,205 (the " Private Placement ") and the subsequent offering (the " Subsequent Offering ") of up to 396,040 new shares (the " Offer Shares ") for gross proceeds of up to NOK 9,544,564.

The Norwegian Financial Supervisory Authority (Nw. Finanstilsynet ) has approved the prospectus of the Company dated 16 May 2018 (the " Prospectus "), for the (i) listing of the New Shares issued in the Private Placement; and (ii) the Subsequent Offering and listing of up to 396,040 Offer Shares.

The subscription period for the Subsequent Offering is expected to commence at 09:00 a.m. CEST on 28 May 2018 and expire at 16:30 p.m. CEST on 8 June 2018.

For more information, please refer to the Prospectus.

The Prospectus will, subject to regulatory restrictions in certain jurisdictions, be available at the following websites: http://soloneiendom.no/investor-relations/  and https://www.dnb.no/bedrift/markets/emisjoner/arkiv/180516-solon.html . Hard copies of the Prospectus may be obtained free of charge by contacting DNB Markets (+47 23 26 81 01).

DNB Markets, a part of DNB Bank ASA, has acted as Manager of the Private Placement and the Subsequent Offering. Advokatfirmaet BAHR is acting as legal advisor.

Contacts:

Andreas Martinussen, CEO

Tel. +47 400 00 405 / email: am@soloneiendom.no

Scott Danielsen, CFO

Tel: +47 952 55 620 / email: sd@soloneiendom.no

***

Important Notice

The contents of this announcement have been prepared by, and are the sole responsibility of, the Company. The Company's financial advisor is acting exclusively for the Company and no one else, and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, or for advice in relation to the transactions, the contents of this announcement or any of the matters  referred to herein. The transactions and the distribution of this announcement and other information in connection with the transactions may be restricted by law in certain jurisdictions. The Company assumes no responsibility in the event there is a violation by any person of such restrictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about, and to observe, any such restrictions. This announcement may not be used for, or in connection with, and does not constitute, any offer of securities for sale in the United States or in any other jurisdiction.

The  transactions have  not, and shall not, be  made  in  any  jurisdiction  or in any circumstances  in  which  such  offer  or  solicitation  would be unlawful. This announcement  is not  for distribution,  directly or  indirectly in  or into any jurisdiction  in which it is unlawful to  make any such offer or solicitation to such  person  or  where  prior  registration  or  approval  is required for that purpose.  No steps have been taken or will be taken relating to the transactions in any jurisdiction in which such steps would be required. Neither the publication  and/or delivery of this  announcement shall under any circumstances imply  that there has been no  change in the affairs of  the Company or that the information contained herein is correct as of any date subsequent to the earlier of  the  date  hereof  and  any  earlier  specified date  with  respect to such information.

This announcement is not for publication or distribution, directly or indirectly, in the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form part of any offer or solicitation to purchase or subscribe for securities in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. The shares to be issued in the transactions have not been and will not be registered  under the United States Securities  Act of 1933, as amended (the "US Securities  Act") or  with any  securities regulatory  authority of any state or other  jurisdiction of the United States, and may  not be offered or sold in the United  States or  to, or for the account of, U.S. persons  (as such  term is defined  in Regulation  S under  the US  Securities Act), except pursuant to an effective registration statement under, or an exemption from the registration requirements  of, the US Securities Act. All offers and sales outside the United States will be made in reliance on Regulation S under the US Securities Act. There will be no public offer of securities in the United States.

This announcement does not constitute an offering circular or prospectus in connection with an offering of securities of the Company. Investors must neither accept any offer for, nor acquire, any securities to which this document refers, unless  they do so on the basis of the information contained in the investor material made available by the Company only to qualified persons in certain jurisdictions  where  an  offer  may  be  made  (if  an  offer  is  made). This announcement does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for, any securities and cannot be relied on for any investment contract or decision.

This information is subject of the disclosure requirements acc. to §5-12 (Norwegian Securities Trading Act).

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. SEA20180516_Solon_Prospekt


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Solon Eiendom ASA via GlobeNewswire
HUG#2193209
GlobeNewswire
globenewswire.com

Last updated on: 17/05/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.